{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:58:12Z","timestamp":1793239092514,"version":"4.5.0"},"reference-count":206,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01CA214278"],"award-info":[{"award-number":["P01CA214278"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54CA244711"],"award-info":[{"award-number":["U54CA244711"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ymthe.2025.03.005","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T20:38:05Z","timestamp":1741639085000},"page":"2123-2140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":198,"title":["From concept to cure: The evolution of CAR-T cell therapy"],"prefix":"10.1016","volume":"33","author":[{"given":"Kisha K.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mito","family":"Tariveranmoshabad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhant","family":"Kadu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Shobaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0241-3557","authenticated-orcid":false,"given":"Carl","family":"June","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.03.005_bib1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fimmu.2011.00021","article-title":"Edward jenner and the small pox vaccine","volume":"2","author":"Smith","year":"2011","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.20517\/2394-4722.2017.41","article-title":"Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead","volume":"3","author":"Oiseth","year":"2017","journal-title":"J.\u00a0Cancer Metastasis Treat."},{"key":"10.1016\/j.ymthe.2025.03.005_bib3","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3389\/fimmu.2019.02965","article-title":"The Intriguing History of Cancer Immunotherapy","volume":"10","author":"Dobosz","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T\u00a0cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib5","first-page":"154","article-title":"The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas","volume":"26","author":"McCarthy","year":"2006","journal-title":"Iowa Orthop. J."},{"key":"10.1016\/j.ymthe.2025.03.005_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3181\/00379727-26-4143","article-title":"On the Pathological Relations Between Cancer and Tuberculosis","volume":"26","author":"Pearl","year":"1928","journal-title":"Exp. Biol. Med. (Maywood)."},{"key":"10.1016\/j.ymthe.2025.03.005_bib7","first-page":"180","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J.\u00a0Urol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer--a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib9","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1172\/JCI32446","article-title":"Adoptive T\u00a0cell therapy for cancer in the clinic","volume":"117","author":"June","year":"2007","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.005_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1098\/rspb.1954.0054","article-title":"Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity","volume":"143","author":"Billingham","year":"1954","journal-title":"Proc. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.ymthe.2025.03.005_bib11","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1084\/jem.169.6.1993","article-title":"T cell memory. Long-term persistence of virus-specific cytotoxic T\u00a0cells","volume":"169","author":"Jamieson","year":"1989","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib12","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/360264a0","article-title":"Lifespan of human lymphocyte subsets defined by CD45 isoforms","volume":"360","author":"Michie","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.005_bib13","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1172\/JCI31446","article-title":"Principles of adoptive T\u00a0cell cancer therapy","volume":"117","author":"June","year":"2007","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.005_bib14","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/bmj.1.5023.841","article-title":"Cancer\u2014a biological approach: III. Viruses associated with neoplastic conditions. IV. Practical applications","volume":"1","author":"Burnet","year":"1957","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ymthe.2025.03.005_bib15","first-page":"329","article-title":"On immunosurveillance in human cancer","volume":"55","author":"Thomas","year":"1982","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib16","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib17","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3389\/fimmu.2017.00829","article-title":"Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models","volume":"8","author":"Decker","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib18","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/1097-0142(196611)19:11<1743::AID-CNCR2820191143>3.0.CO;2-U","article-title":"Effect of leukocytes on transplantability of human cancer","volume":"19","author":"Southam","year":"1966","journal-title":"Cancer"},{"key":"10.1016\/j.ymthe.2025.03.005_bib19","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1126\/science.143.3606.551","article-title":"Human Experimentation: Cancer Studies at Sloan-Kettering Stir Public Debate on Medical Ethics","volume":"143","author":"Langer","year":"1964","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.005_bib20","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1177\/17470161241235772","article-title":"The Belmont Report doesn\u2019t need reform, our moral imagination does","volume":"20","author":"Serpico","year":"2024","journal-title":"Res. Ethics"},{"key":"10.1016\/j.ymthe.2025.03.005_bib21","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.omtm.2023.06.007","article-title":"A method for polyclonal antigen-specific T\u00a0cell-targeted genome editing (TarGET) for adoptive cell transfer applications","volume":"30","author":"Palianina","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.005_bib24","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib25","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib26","volume":"10","author":"Chesney","year":"2022","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.03.005_bib27","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib28","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2014.0374","article-title":"T cell engineering as therapy for cancer and HIV: our synthetic future","volume":"370","author":"June","year":"2015","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.ymthe.2025.03.005_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1018962","article-title":"Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?","volume":"13","author":"Kazemi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib31","first-page":"113","article-title":"The Significance of Pneumococcal Types","volume":"27","author":"Griffith","year":"1928","journal-title":"J.\u00a0Hyg."},{"key":"10.1016\/j.ymthe.2025.03.005_bib32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1084\/jem.79.2.137","article-title":"STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES : INDUCTION OF TRANSFORMATION BY A DESOXYRIBONUCLEIC ACID FRACTION ISOLATED FROM PNEUMOCOCCUS TYPE III","volume":"79","author":"Avery","year":"1944","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib33","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0042-6822(68)90142-6","article-title":"SV40\u00a0T antigen induction and transformation in human fibroblast cell strains","volume":"36","author":"Stuart","year":"1968","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2025.03.005_bib34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/newbio237035a0","article-title":"Virus recovery in chicken cells tested with Rous sarcoma cell DNA","volume":"237","author":"Hill","year":"1972","journal-title":"Nat. New Biol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib35","series-title":"Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer","first-page":"27","year":"2002"},{"key":"10.1016\/j.ymthe.2025.03.005_bib36","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.175.4025.949","article-title":"Gene therapy for human genetic disease?","volume":"175","author":"Friedmann","year":"1972","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.005_bib37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0092-8674(83)90344-6","article-title":"Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus","volume":"33","author":"Mann","year":"1983","journal-title":"Cellule"},{"key":"10.1016\/j.ymthe.2025.03.005_bib38","first-page":"2895","article-title":"Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production","volume":"6","author":"Miller","year":"1986","journal-title":"Mol. Cel. Biol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.molimm.2022.08.002","article-title":"From magic bullets to modern therapeutics: Paul Ehrlich, the German immunobiologist and physician coined the term \u2018complement\u2019","volume":"150","author":"Zipfel","year":"2022","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib40","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41423-024-01168-4","article-title":"Legacy of the discovery of the T-cell receptor: 40 years of shaping basic immunology and translational work to develop novel therapies","volume":"21","author":"Shi","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib41","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1021\/ja01867a018","article-title":"A theory of the structure and process of formation of antibodies","volume":"62","author":"Pauling","year":"1940","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ymthe.2025.03.005_bib42","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.4049\/jimmunol.129.5.2293","article-title":"Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody","volume":"129","author":"Allison","year":"1982","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib43","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1084\/jem.157.2.705","article-title":"Clonotypic structures involved in antigen-specific human T\u00a0cell function. Relationship to the T3 molecular complex","volume":"157","author":"Meuer","year":"1983","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib44","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1084\/jem.157.4.1149","article-title":"The major histocompatibility complex-restricted antigen receptor on T\u00a0cells. I. Isolation with a monoclonal antibody","volume":"157","author":"Haskins","year":"1983","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib45","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/308149a0","article-title":"Isolation of cDNA clones encoding T\u00a0cell-specific membrane-associated proteins","volume":"308","author":"Hedrick","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.005_bib46","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/308145a0","article-title":"A human T\u00a0cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains","volume":"308","author":"Yanagi","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.005_bib47","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1073\/pnas.73.10.3628","article-title":"Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions","volume":"73","author":"Hozumi","year":"1976","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.005_bib48","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/248701a0","article-title":"Restriction of in\u00a0vitro T\u00a0cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system","volume":"248","author":"Zinkernagel","year":"1974","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.005_bib49","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1002\/eji.201242606","article-title":"Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies","volume":"42","author":"Aleksic","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib50","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib51","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T\u00a0cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib52","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D'Angelo","year":"2024","journal-title":"The Lancet"},{"key":"10.1016\/j.ymthe.2025.03.005_bib53","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1440-1711.1999.00835.x","article-title":"The role of B7 costimulation in T-cell immunity","volume":"77","author":"Harris","year":"1999","journal-title":"Immunol. Cel Biol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib54","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1146\/annurev.immunol.21.120601.141110","article-title":"T Cell Anergy","volume":"21","author":"Schwartz","year":"2003","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib55","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.coi.2010.02.013","article-title":"Inflammatory cytokines as a third signal for T\u00a0cell activation","volume":"22","author":"Curtsinger","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib56","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.4049\/jimmunol.136.9.3282","article-title":"A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes","volume":"136","author":"Martin","year":"1986","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib57","first-page":"650","article-title":"Stimulation of T\u00a0cells through the CD3\/T-cell receptor complex: role of cytoplasmic calcium, protein kinase C translocation, and phosphorylation of pp60c-src in the activation pathway","volume":"7","author":"Ledbetter","year":"1987","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib58","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1073\/pnas.86.4.1333","article-title":"CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines\/cytokines","volume":"86","author":"Thompson","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.005_bib59","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0167-5699(90)90085-N","article-title":"Role of the CD28 receptor in T-cell activation","volume":"11","author":"June","year":"1990","journal-title":"Immunol. Today"},{"key":"10.1016\/j.ymthe.2025.03.005_bib60","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1089\/hum.2014.2533","article-title":"Toward synthetic biology with engineered T\u00a0cells: a long journey just begun","volume":"25","author":"June","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.005_bib61","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2004-04-1596","article-title":"The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation","volume":"105","author":"Riley","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.005_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/v13081528","article-title":"Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives","volume":"13","author":"Labb\u00e9","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2025.03.005_bib63","series-title":"Gene Therapy Protocols","first-page":"241","article-title":"Methods for retrovirus-mediated gene transfer into primary T-lymphocytes","author":"Sadelain","year":"1997"},{"key":"10.1016\/j.ymthe.2025.03.005_bib64","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In\u00a0vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.005_bib65","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1038\/498S17a","article-title":"Perspective: Assembly line immunotherapy","volume":"498","author":"Levine","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.005_bib66","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2025.03.005_bib67","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.005_bib68","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","article-title":"The cytoplasmic domain of the T\u00a0cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways","volume":"64","author":"Irving","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.03.005_bib69","doi-asserted-by":"crossref","first-page":"8905","DOI":"10.1073\/pnas.88.20.8905","article-title":"T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins","volume":"88","author":"Letourneur","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.005_bib70","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/0092-8674(91)90327-U","article-title":"Cellular immunity to HIV activated by CD4 fused to T\u00a0cell or Fc receptor polypeptides","volume":"64","author":"Romeo","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.03.005_bib71","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.005_bib72","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/1535370215584936","article-title":"From humble beginnings to success in the\u00a0clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy","volume":"240","author":"Firor","year":"2015","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib73","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.03.005_bib74","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00002371-200011000-00004","article-title":"Coupling CD28 co-stimulation to immunoglobulin T-cell receptor molecules: the dynamics of T-cell proliferation and death","volume":"23","author":"Beecham","year":"2000","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.ymthe.2025.03.005_bib75","first-page":"1976","article-title":"T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis","volume":"61","author":"Hombach","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.03.005_bib76","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1182\/blood-2002-04-1041","article-title":"Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors","volume":"100","author":"Haynes","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.005_bib77","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR\u03b6\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib78","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","article-title":"CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in\u00a0vivo persistence and antitumor efficacy of adoptively transferred T\u00a0cells","volume":"66","author":"Kowolik","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.03.005_bib79","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.03.005_bib80","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ymthe.2018.01.022","article-title":"In\u00a0Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia","volume":"26","author":"Cheng","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.005_bib81","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ymthe.2025.03.005_bib82","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the Antigen Density Requirement for CAR T-cell Activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2025.03.005_bib83","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T\u00a0cells and increased antileukemic efficacy in\u00a0vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.005_bib84","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121322","article-title":"4-1BB enhancement of CAR T function requires NF-\u03baB and TRAFs","volume":"3","author":"Li","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.03.005_bib85","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ymthe.2020.10.008","article-title":"Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7","volume":"29","author":"Amatya","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.005_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1034707","article-title":"Next generations of CAR-T cells - new therapeutic opportunities in hematology?","volume":"13","author":"Tomasik","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib87","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1038\/s41375-024-02392-7","article-title":"Third-generation anti-CD19 CAR T\u00a0cells for relapsed\/refractory chronic lymphocytic leukemia: a phase 1\/2 study","volume":"38","author":"Derigs","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2025.03.005_bib88","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.005_bib89","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.omto.2017.12.003","article-title":"CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity","volume":"8","author":"Kueberuwa","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2025.03.005_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.609421","article-title":"The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory\/Recurrent Multiple Myeloma","volume":"12","author":"Duan","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib91","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/s41467-019-10097-0","article-title":"Synthetic TRuC receptors engaging the complete T\u00a0cell receptor for potent anti-tumor response","volume":"10","author":"Baeuerle","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.005_bib92","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-023-02452-y","article-title":"Mesothelin-targeting T\u00a0cell receptor fusion construct cell therapy in refractory solid tumors: phase 1\/2 trial interim results","volume":"29","author":"Hassan","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib93","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.ymthe.2006.08.068","article-title":"Preliminary results of a pilot phase I clinical trial of adoptive immunotherapy for B cell lymphoma using CD8+ T\u00a0cells genetically modified to express a chimeric T\u00a0cell receptor recognizing CD20","volume":"13","author":"Press","year":"2006","journal-title":"Am. Soc. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.005_bib94","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm827","article-title":"Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15","volume":"9","author":"Brentjens","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib95","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor\u2013modified T\u00a0cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.005_bib96","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T\u00a0cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.005_bib97","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T\u00a0cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib98","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T\u00a0cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib99","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T\u00a0cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.005_bib100","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2321678","article-title":"First pediatric B-acute lymphoblastic leukemia patient treated with anti-CD19 chimeric antigen receptor T-cell therapy: Long-term remission or early cure?","volume":"20","author":"Bouzianas","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ymthe.2025.03.005_bib101","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T\u00a0cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib102","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib103","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib104","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib105","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1182\/blood-2021-148078","article-title":"Long-Term (\u22654 Year and \u22655 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)","volume":"138","author":"Jacobson","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.005_bib106","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.03.005_bib107","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood.2019000905","article-title":"High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy","volume":"134","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.005_bib108","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.005_bib109","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib110","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib111","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/MOH.0000000000000685","article-title":"Role of chimeric antigen receptor T-cell therapy: bridge to transplantation or stand-alone therapy in pediatric acute lymphoblastic leukemia","volume":"28","author":"Qayed","year":"2021","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib112","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.21.00917","article-title":"Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia","volume":"39","author":"Roddie","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib113","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib114","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-Year Follow-Up of KTE-X19 in Patients With Relapsed\/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study","volume":"41","author":"Wang","year":"2023","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib115","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T\u00a0cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib116","volume":"14","author":"Molinos-Quintana","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib117","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212567","article-title":"Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges","volume":"8","author":"Makita","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.ymthe.2025.03.005_bib118","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","article-title":"Management guidelines for paediatric patients receiving chimeric antigen receptor T\u00a0cell therapy","volume":"16","author":"Mahadeo","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib119","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/d41573-019-00090-z","article-title":"The global pipeline of cell therapies for cancer","volume":"18","author":"Xin Yu","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.03.005_bib120","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib121","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib122","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T Cells for Next-Generation Cancer Therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.03.005_bib123","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T\u00a0cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib124","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.trecan.2024.05.007","article-title":"Future perspectives on engineered T\u00a0cells for cancer","volume":"10","author":"Posey","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ymthe.2025.03.005_bib125","article-title":"Beyond the blood: expanding CAR T cell therapy to solid tumors","author":"Uslu","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib126","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2025.03.005_bib127","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib128","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T\u00a0cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib129","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib130","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T\u00a0cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.005_bib131","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","article-title":"Intravenous and intracranial GD2-CAR T\u00a0cells for H3K27M+ diffuse midline gliomas","volume":"637","author":"Monje","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.005_bib132","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T\u00a0cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib133","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib134","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.005_bib135","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib136","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","article-title":"An NK-like CAR T\u00a0cell transition in CAR T\u00a0cell dysfunction","volume":"184","author":"Good","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.03.005_bib137","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T\u00a0cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.005_bib138","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1200\/JCO.2024.42.16_suppl.7004","article-title":"Safety and efficacy of armored huCART19-IL18 in patients with relapsed\/refractory lymphomas that progressed after anti-CD19 CAR T\u00a0cells","volume":"42","author":"Svoboda","year":"2024","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib139","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2025.03.005_bib140","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1074-7613(00)80170-3","article-title":"Abrogation of TGFbeta signaling in T\u00a0cells leads to spontaneous T\u00a0cell differentiation and autoimmune disease","volume":"12","author":"Gorelik","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.03.005_bib141","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-Negative TGF-beta Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.005_bib142","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T\u00a0cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib143","doi-asserted-by":"crossref","DOI":"10.1172\/JCI169655","article-title":"Antitumor activity of AZD0754, a dnTGFbetaRII-armored, STEAP2-targeted CAR-T cell therapy","volume":"133","author":"Zanvit","year":"2023","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.005_bib144","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T\u00a0cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.005_bib145","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.cell.2018.10.024","article-title":"Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function","volume":"175","author":"Shifrut","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.03.005_bib146","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T\u00a0cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.005_bib147","doi-asserted-by":"crossref","DOI":"10.1126\/science.abn5647","article-title":"Enhanced T\u00a0cell effector activity by targeting the Mediator kinase module","volume":"378","author":"Freitas","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.005_bib148","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41586-022-05126-w","article-title":"RASA2 ablation in T\u00a0cells boosts antigen sensitivity and long-term function","volume":"609","author":"Carnevale","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.005_bib149","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ccell.2022.06.001","article-title":"Genome-wide CRISPR screens of T\u00a0cell exhaustion identify chromatin remodeling factors that limit T\u00a0cell persistence","volume":"40","author":"Belk","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.03.005_bib150","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2218632120","article-title":"Combined disruption of T\u00a0cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T\u00a0cells","volume":"120","author":"Mai","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.005_bib151","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20232368","article-title":"Induction of immortal-like and functional CAR T\u00a0cells by defined factors","volume":"221","author":"Wang","year":"2024","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib152","article-title":"Degradation of IKAROS prevents epigenetic progression of T\u00a0cell exhaustion in a novel antigen-specific assay","volume":"5","author":"Tay","year":"2024","journal-title":"Cell Rep Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib153","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib154","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib155","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T Cells Expressing CD19\/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2025.03.005_bib156","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1158\/2159-8290.CD-22-0964","article-title":"CD19\/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive\/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma","volume":"13","author":"Larson","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2025.03.005_bib157","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T\u00a0cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib158","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","article-title":"Bispecific CAR T\u00a0cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.005_bib159","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg7962","article-title":"Engineered T\u00a0cells secreting anti-BCMA T\u00a0cell engagers control multiple myeloma and promote immune memory in\u00a0vivo","volume":"16","author":"D\u00edez-Alonso","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib160","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.03.005_bib161","doi-asserted-by":"crossref","DOI":"10.1126\/science.adl4237","article-title":"Programming tissue-sensing T\u00a0cells that deliver therapies to the brain","volume":"386","author":"Simic","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.005_bib162","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.cell.2022.03.023","article-title":"Modular design of synthetic receptors for programmed gene regulation in cell therapies","volume":"185","author":"Zhu","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.03.005_bib163","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41586-024-08366-0","article-title":"Engineered receptors for soluble cellular communication and disease sensing","volume":"638","author":"Piraner","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.005_bib164","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib165","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2-M","article-title":"Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer","volume":"83","author":"Kammula","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.ymthe.2025.03.005_bib166","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1126\/science.aar3246","article-title":"Selective targeting of engineered T\u00a0cells using orthogonal IL-2 cytokine-receptor complexes","volume":"359","author":"Sockolosky","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.005_bib167","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg6986","article-title":"A human orthogonal IL-2 and IL-2Rbeta system enhances CAR T\u00a0cell expansion and antitumor activity in a murine model of leukemia","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib168","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-022-04801-2","article-title":"Potentiating adoptive cell therapy using synthetic IL-9 receptors","volume":"607","author":"Kalbasi","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.005_bib169","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112512","article-title":"Therapeutic potential of CAR T\u00a0cell in malignancies: A scoping review","volume":"146","author":"Mehrabadi","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ymthe.2025.03.005_bib171","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb6295","article-title":"Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide","volume":"13","author":"Jan","year":"2021","journal-title":"Sci. Transl Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib172","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.005_bib173","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM197907053010102","article-title":"Immune interferon in the circulation of patients with autoimmune disease","volume":"301","author":"Hooks","year":"1979","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib174","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis. Rheum."},{"key":"10.1016\/j.ymthe.2025.03.005_bib175","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib176","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib177","first-page":"550","article-title":"CD19-targeted chimeric antigen receptor T\u00a0cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Medizinrecht"},{"key":"10.1016\/j.ymthe.2025.03.005_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109173","article-title":"Basing on uPAR-binding fragment to design chimeric antigen receptors triggers antitumor efficacy against uPAR expressing ovarian cancer cells","volume":"117","author":"Wang","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ymthe.2025.03.005_bib179","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","article-title":"Senolytic CAR T\u00a0cells reverse senescence-associated pathologies","volume":"583","author":"Amor","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.005_bib180","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add1951","article-title":"NKG2D-CAR T\u00a0cells eliminate senescent cells in aged mice and nonhuman primates","volume":"15","author":"Yang","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib181","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj6251","article-title":"Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control","volume":"10","author":"Lu","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2025.03.005_bib182","first-page":"467","article-title":"Long-term in\u00a0vivo survival of receptor-modified syngeneic T\u00a0cells in patients with human immunodeficiency virus infection","volume":"96","author":"Walker","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.005_bib183","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V96.3.785.015k10_785_793","article-title":"Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T\u00a0cells in human immunodeficiency virus-infected subjects","volume":"96","author":"Mitsuyasu","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.005_bib184","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1126\/science.272.5270.1939","article-title":"Antiviral effect and ex\u00a0vivo CD4+ T\u00a0cell proliferation in HIV-positive patients as a result of CD28 costimulation","volume":"272","author":"Levine","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.005_bib185","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1126\/science.276.5310.273","article-title":"Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T\u00a0cells","volume":"276","author":"Carroll","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.005_bib186","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.4049\/jimmunol.158.11.5545","article-title":"Intrinsic resistance to T\u00a0cell infection with HIV type 1 induced by CD28 costimulation","volume":"158","author":"Riley","year":"1997","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib187","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene Editing of CCR5 in Autologous CD4\u00a0T Cells of Persons Infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib188","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nm0102-47","article-title":"Adoptive transfer of costimulated CD4+ T\u00a0cells induces expansion of peripheral T\u00a0cells and decreased CCR5 expression in HIV infection","volume":"8","author":"Levine","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib189","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.clim.2004.03.004","article-title":"Immune reconstitution following autologous transfers of CD3\/CD28 stimulated CD4+ T\u00a0cells to HIV-infected persons","volume":"111","author":"Bernstein","year":"2004","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib190","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41421-024-00658-z","article-title":"Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I, multicenter, single-arm, open-label study","volume":"10","author":"Mao","year":"2024","journal-title":"Cell Discov."},{"key":"10.1016\/j.ymthe.2025.03.005_bib191","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/PPO.0000000000000511","article-title":"Off-the-Shelf Chimeric Antigen Receptor T Cells: How Do We Get There?","volume":"27","author":"Watanabe","year":"2021","journal-title":"Cancer J."},{"key":"10.1016\/j.ymthe.2025.03.005_bib192","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.ymthe.2025.03.005_bib193","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/cell.2023.0041","article-title":"Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor T Cells: The Intersection of Stem Cells and Immunotherapy","volume":"25","author":"Lahimchi","year":"2023","journal-title":"Cell. Reprogram."},{"key":"10.1016\/j.ymthe.2025.03.005_bib194","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib195","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T\u00a0cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2025.03.005_bib196","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjh.19988","article-title":"mRNA-laden lipid nanoparticle-enabled humanized CD19 CAR-T-cell engineering for the eradication of leukaemic cells","volume":"206","author":"Chen","year":"2025","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymthe.2025.03.005_bib197","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T\u00a0cells produced in\u00a0vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.005_bib198","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1016\/j.ymthe.2021.06.004","article-title":"Highly efficient CD4+ T\u00a0cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs","volume":"29","author":"Tomb\u00e1cz","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.005_bib199","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1126\/science.aay5967","article-title":"An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors","volume":"367","author":"Reinhard","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.005_bib200","article-title":"Ultralow-dose binary oncolytic\/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies","volume":"9","author":"Wang","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2025.03.005_bib201","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood-2007-12-128751","article-title":"Resistance of mature T\u00a0cells to oncogene transformation","volume":"112","author":"Newrzela","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.005_bib202","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T\u00a0cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib203","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib204","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.005_bib205","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1182\/blood.2021010858","article-title":"Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T\u00a0cells","volume":"138","author":"Micklethwaite","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.005_bib206","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/356607a0","article-title":"CD28-mediated signalling co-stimulates murine T\u00a0cells and prevents induction of anergy in T-cell clones","volume":"356","author":"Harding","year":"1992","journal-title":"Nature"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625001790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625001790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:42:40Z","timestamp":1792687360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625001790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":206,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1525001625001790"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.005","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From concept to cure: The evolution of CAR-T cell therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}